Compare Citius Pharmaceuticals Inc (CTXR) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Endeavour Silver Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Endeavour Silver Corp trades at $8.78 (market cap $2.54B). The key difference: Endeavour Silver Corp is far larger — about 186.5× Citius Pharmaceuticals Inc's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Endeavour Silver Corp for 25 Days on average.
| CTXR | EXK | |
|---|---|---|
Market Cap | $13.62M | $2.54B |
Volume | 132,438 | 7,077,330 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $14.12 |
52-Week Low | $0.48 | $7.07 |
Typical Hold Time | 16 Days | 25 Days |
Enterprise Value | $3.79M | $2.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Endeavour Silver (EXK) trades at $8.32, down 4.04% today, amid a bearish technical signal. The company reported mixed Q2 2026 earnings, matching estimates with $0.15 EPS, but showed strong revenue growth and improved profitability in 2026. Recent news highlights operational progress at Terronera and Kolpa mines, though temporary disruptions occurred. Analyst consensus remains strongly bullish with a $10.50 price target.
Outlook is cautiously optimistic driven by production growth and favorable metal prices, but risks include operational disruptions and high valuation multiples. The stock offers potential upside from current levels if execution continues, but volatility from commodity prices and mine-specific issues persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
